Actualité dans les tumeurs cérébrales - AFPHB. Brain Tumor, Prof. J.F... · Actualité. dans ....
43
Actualité dans les tumeurs cérébrales Prof J-Fr. BAURAIN Medical Oncology Department BSOP 2014 Blankenberge 23 Janvier 2015 UCL Université catholique de Louvain
Transcript of Actualité dans les tumeurs cérébrales - AFPHB. Brain Tumor, Prof. J.F... · Actualité. dans ....
Actualité
dans
les tumeurs cérébrales
Prof J-Fr. BAURAINMedical Oncology Department
BSOP 2014Blankenberge23 Janvier 2015
UCLUniversitécatholiquede Louvain
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute Blankenberg - 15/01/23
Tumours in the Brain
HeadacheHTIC
Focal SignsEpilepsy, palsy
Clinic
Imagery
Brain MRIT1, T2, Flair, Gado
Nuclear MedecinePET-methionine
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute Blankenberg - 15/01/23
Tumours in the Brain
young patientsmelanoma
older patientslung cancers
Secondary lesions(metastases)
Primary lesions(brain tumour)
nerve, meningiaschwanoma, meningioma
glial cellsastrocytoma, oligodendroglioma
WHO 2007Blankenberg - 15/01/23
WHO Classification of CNS Tumours
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
WHO 2007Blankenberg - 15/01/23
Proportion of the Different CNS Tumours
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
xxxBlankenberg - 15/01/23
Anatomopathology of Glial Tumours
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
xxxBlankenberg - 15/01/23
Overall Survival according to Grade
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
xxxBlankenberg - 15/01/23
Grading = histological classification
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Subjectivity in the interpretationastrocytoma vs mixed gliomadiffuse astrocytoma vs pilocytic glioma
Interobserver variability10 cases10 anatomapathologistsless than 10% concordance
Necessity to have biomarkersdiagnosticprognosticpredictive
Reifenberg G., BANO 2013Blankenberg - 15/01/23
Genetic Anomalies in Glial Tumors
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
Clinically Relevant Biomarkers
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Reifenberg G., BANO 2013
NOA-08 trial, W. WickBlankenberg - 15/01/23
MGMT promotor Methylation as a Predictive Marker
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Cairncross J,et al. JNCI 1998Blankenberg - 15/01/23
1p / 19q loss as Predictive Marker
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Hartmann et al. , Acta Neuropathol 2010Blankenberg - 15/01/23
IDH1 mutation as a Prognostic Marker
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
Treatment of Glial Tumours
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
SurgeryComplete resectionDiagnostic
Blankenberg - 15/01/23
Treatment of Glial Tumours
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Radiotherapystandard3D
SurgeryComplete resectionDiagnostic
Blankenberg - 15/01/23
Treatment of Glial Tumours
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
SurgeryComplete resectionDiagnostic
Radiotherapystandard3D
ChemotherapyPBV / PCVTMZ
Blankenberg - 15/01/23
Treatment of Low Grade Gliomas (LGG), male 58 years
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
Pronostic Markers of Low Grade Gliomas (LGG)
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
Pronostic Markers of Low Grade Gliomas (LGG)
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
Pronostic Markers of Low Grade Gliomas (LGG)
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Cairncross J,et al. JNCI 1998
Blankenberg - 15/01/23
Treatment of Low Grade Gliomas (LGG)
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
High Risk LGG : added value of Chemotherapy ?
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
Chemotherapy in place of Radiotherapy : EORTC 26033
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
Treatment of Low Grade EORTC 26033 (LGG)
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
Treatment of High Grade Gliomas (AA/AOD)
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
Important the 1p / 19q Loss in grade III tumours
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
Treatment of High Grade Gliomas (AA/AOD)
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
Why 1p / 19q Loss associated with a better outcome
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
Treatment of High Grade Gliomas : CATNON Study
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
Treatment of Grade III Gliomas
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
Treatment of Glioblastoma
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Nothing has changed
Blankenberg - 15/01/23
Genetic Classification of GBM
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
Genetic Classification of GBM
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
Treatment of High Grade Gliomas (GBM)
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
Treatment of High Grade Gliomas : Stupp’s Study
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
Treatment of High Grade Gliomas : Stupp’s Study
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
Function of MGMT protein
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
Methylation of the Promoter from MGMT Gene
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
Importance of MGMT in Prognosis
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
New Treatment in GBM : Cilengitide (Centric Trial)
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
New Treatment in GBM : Avastin
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
New Treatment in GBM : Avastin, BELOB Trial
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
Blankenberg - 15/01/23
In Conclusion
King Albert II Cancer Institute, Université catholique de Louvain, Bruxelles, Belgium - This presentation is the intellectual propriety of Prof J-Fr. BAURAIN , Contact [email protected] for permission to reprint and/or distribute
- Treatment of glial tumors needs multidisciplinar team
- Cure of these tumors remains a hope
- High risk low grade tumors need an adjuvant treatment
- Grade III glial tumours must be treated according to 1p/19q
- Treatment of GBM remains a challenge
- Around 10% of long survivors are seen in methMGMT GBM
